Characterization of Novel Nitazene Recreational Drugs: Insights into Their Risk Potential from in Vitro µ-Opioid Receptor Assays and in Vivo Behavioral Studies in Mice
Open accessAbstract
[H]DAMGO) binding assays in rat brain tissue. MOR activation (potency and efficacy) was studied by means of a cell-based β-arrestin 2 recruitment assay. For seven nitazenes, including etonitazene, opioid-like pharmacodynamic effects (antinociception, locomotor activity, body temperature changes) were evaluated after subcutaneous administration in male C57BL/6 J mice. The results showed that all nitazenes bound to MOR with nanomolar affinities, and the functional potency of several of them was comparable to or exceeded that of fentanyl. In vivo, dose-dependent effects were observed for antinociception, locomotor activity, and body temperature changes in mice. SAR insights included the high opioid-like activity of methionitazene, iso-butonitazene, sec-butonitazene, and the etonitazene analogues 1-ethyl-pyrrolidinylmethyl N-desalkyl etonitazene and ethylene etonitazene. The most potent analogue of the panel across all functional assays was α'-methyl etonitazene. Taken together, through critical pharmacological evaluation, this work provides a framework for strengthened preparedness and risk assessments of current and future nitazenes that have the potential to cause harm to users.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Minimal structural differences at the benzimidazole core, the N,N-dialkylaminoethyl side chain, and the para-substituted benzyl ring can profoundly alter receptor binding, potency, metabolism, and expected toxicity.
“Although nitazenes are often discussed as a class, minimal structural differences at the benzimidazole core, the N, N- dialkylaminoethyl side chain, as well as the para-substituted benzyl ring can profoundly alter receptor binding, potency, metabolism, and expected toxicity [17].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [17]
The Conclusions (page unavailable) report that changes to the benzimidazole substituent, amino side chain, and benzylbenzimidazole linker alter opioid activity; the Results report differences in µ-opioid receptor affinity and potency. The paper does not establish that these structural changes alter metabolism, and the Discussion says that specific adverse effects such as respiratory depression were beyond the study’s scope. It suggests overdose risk from high receptor potency and efficacy rather than measuring changes in toxicity. (LLM, conf=0.88)
Experimental — accuracy not yet measuredMany nitazenes demonstrate MOR binding affinities comparable to, or exceeding, those of morphine and fentanyl.
“Many nitazenes demonstrate MOR binding affinities comparable to, or exceeding, those of morphine and fentanyl [29,30,31,32,33].”
From Nitazenes: The Emergence of a Potent Synthetic Opioid Threat (2025) · cites this paper as [30]
The Results (page unavailable) report nanomolar MOR binding affinities for all tested nitazenes and say that fentanyl and morphine were among the reference opioids measured. The available binding passages do not establish that many nitazenes have affinities comparable to or greater than both drugs. The Results do compare some nitazenes with fentanyl on functional potency, but potency is not binding affinity. (LLM, conf=0.78)
Experimental — accuracy not yet measuredThis potency variation may partially explain the absence of compounds such as flunitazene and ethyleneoxynitazene in a substantial number of NPS Discovery biospecimens.
“This may partially explain the absence of compounds such as flunitazene and ethyleneoxynitazene in a substantial number of NPS Discovery biospecimens [37].”
From Temporal and geographical patterns of nitazene detections in drug samples and biospecimens in the United States, 2019–2024 (2026) · cites this paper as [37]
The Discussion (page unavailable) ranks ethyleneoxynitazene among the less potent analogues, and the Conclusions report decreased in vitro and in vivo opioid activity for it. The paper does not establish that potency explains its absence from NPS Discovery biospecimens, or provide a corresponding finding for flunitazene; searches for those terms and biospecimens found no supporting passage. (LLM, conf=0.85)
Experimental — accuracy not yet measuredNitazenes act as highly potent and selective μ-opioid receptor (MOR) agonists, the primary site of action for therapeutic and adverse opioid effects.
“Nitazenes act as highly potent and selective μ-opioid receptor (MOR) agonists, the primary site of action for therapeutic and adverse opioid effects.”
From Nitazenes: The Emergence of a Potent Synthetic Opioid Threat (2025) · cites this paper as [30]
The Results report that all tested nitazenes activated MOR, while the Conclusions say most newly studied compounds had in vitro potency comparable to or greater than fentanyl. The Methods state that MOR selectivity had previously been demonstrated for many nitazenes, but this study did not test other opioid receptors. The copy does not establish that MOR is the primary site of both therapeutic and adverse opioid effects, and potency varied substantially across the compounds. (LLM, conf=0.84)
Experimental — accuracy not yet measuredIt is possible to predict emerging nitazene analogues using advances in forensic intelligence and artificial intelligence tools.
“Nowadays, with advances in forensic intelligence and artificial intelligence tools, it is possible to predict emerging nitazene analogues, as demonstrated in recent studies [30,39]”
From Nitazenes: The Emergence of a Potent Synthetic Opioid Threat (2025) · cites this paper as [30]
The Introduction (page not specified) describes a predictive approach: the authors selected possible future nitazene analogues, four of which were subsequently identified on the recreational drug market. It does not attribute that prediction to artificial intelligence tools or advances in forensic intelligence; the approach described is based on structural variations and pharmacological testing. (LLM, conf=0.87)
Experimental — accuracy not yet measured
In vivo studies of etonitazene and related analogs demonstrate classic opioid-like pharmacodynamic effects, including antinociception, altered locomotor activity, and reduced body temperature in animal models.
“In vivo studies of etonitazene and related analogs demonstrate classic opioid-like pharmacodynamic effects, including antinociception, altered locomotor activity, and reduced body temperature in animal models [17].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Fluorine in medicinal chemistry
Purser, S., Moore, P. R., Swallow, S., & Gouverneur, V. (2007) · Chemical Society Reviews · doi:10.1039/b610213c · Cited by 7,616 · see citing works
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., et al. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000410 · Cited by 5,939 · see citing works
Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14153 · Cited by 1,338 · see citing works
ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020
Lilley, E., Stanford, S. C., Kendall, D. E., Alexander, S. P. H., Cirino, G., Docherty, J. R., George, C. H., Insel, P. A., Izzo, A. A., Ji, Y., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15178 · Cited by 1,214 · see citing works
The ARRIVE guidelines 2019: updated guidelines for reporting animal researchPreprint
du Sert, N. P., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/703181 · Cited by 1,042 · see citing works
Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs
Volpe, D. A., Tobin, G. A. M., Mellon, R. D., Katki, A. G., Parker, R. J., Colatsky, T., Kropp, T. J., & Verbois, S. L. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.12.007 · Cited by 446 · see citing works
Gillis, A., Gondin, A. B., Kliewer, A., Sanchez, J., Lim, H. D., Alamein, C., Manandhar, P., Santiago, M., Fritzwanker, S., Schmiedel, F., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aaz3140 · Cited by 365 · see citing works
Vandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161 · see citing works
Self-citationIsotonitazene Quantitation and Metabolite Discovery in Authentic Forensic Casework
Krotulski, A. J., Papsun, D. M., Kacinko, S. L., & Logan, B. K. (2020) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa016 · Cited by 146 · see citing works
DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles
Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00037 · Cited by 141 · see citing works
Self-citationBlanckaert, P., Cannaert, A., Van Uytfanghe, K., Hulpia, F., Deconinck, E., Van Calenbergh, S., & Stove, C. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2738 · Cited by 116 · see citing works
Self-citationMurphy, C. D., & Sandford, G. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1020295 · Cited by 93 · see citing works
Montanari, E., Madeo, G., Pichini, S., Busardò, F. P., & Carlier, J. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000970 · Cited by 89 · see citing works
Nitazenes—Heralding a Second Wave for the UK Drug-Related Death Crisis?
Holland, A., Copeland, C. S., Shorter, G. W., Connolly, D. J., Wiseman, A., Mooney, J., Fenton, K., & Harris, M. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00001-x · Cited by 86 · see citing works
Thoren, K. L., Colby, J. M., Shugarts, S. B., Wu, A. H. B., & Lynch, K. L. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.241315 · Cited by 84 · see citing works
Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients
Amaducci, A., Aldy, K., Campleman, S. L., Li, S., Meyn, A., Abston, S., Culbreth, R. E., Krotulski, A., Logan, B., Wax, P., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.31264 · Cited by 84 · see citing works
Tseng, C., Baillie, G. L., Donvito, G., Mustafa, M. A., Juola, S. E., Zanato, C., Massarenti, C., Dall’Angelo, S., Harrison, W. T. A., Lichtman, A. H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00252 · Cited by 82 · see citing works
Vandeputte, M. M., Krotulski, A. J., Walther, D., Glatfelter, G. C., Papsun, D., Walton, S. E., Logan, B. K., Baumann, M. H., & Stove, C. P. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03276-4 · Cited by 80 · see citing works
Self-citationRicarte, A., Dalton, J. A. R., & Giraldo, J. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00890 · Cited by 72 · see citing works
Hunger, A., Kebrle, J., Rossi, A., & Hoffmann, K. J. (1960) · Helvetica Chimica Acta · doi:10.1002/hlca.19600430412 · Cited by 70 · see citing works
Über Benzimidazolderivate mit starker analgetischer Wirkung
Gross, F., & Turrian, H. (1957) · Cellular and Molecular Life Sciences · doi:10.1007/bf02161117 · Cited by 62 · see citing works
De Vrieze, L. M., Walton, S. E., Pottie, E., Papsun, D., Logan, B. K., Krotulski, A. J., Stove, C. P., & Vandeputte, M. M. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03774-7 · Cited by 58 · see citing works
Self-citationPharmacological Research as a Key Component in Mitigating the Opioid Overdose Crisis
Baumann, M. H., Kopajtic, T. A., & Madras, B. K. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.09.006 · Cited by 57 · see citing works
Self-citationVasudevan, L., Vandeputte, M., Deventer, M., Wouters, E., Cannaert, A., & Stove, C. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113910 · Cited by 55 · see citing works
Self-citationPottie, E., Dedecker, P., & Stove, C. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114251 · Cited by 55 · see citing works
Self-citationMu-Opioid Receptor Selective Superagonists Produce Prolonged Respiratory Depression
Malcolm, N. J., Palkovic, B., Sprague, D. J., Calkins, M. M., Lanham, J. K., Halberstadt, A. L., Stucke, A. G., & McCorvy, J. D. (2023) · iScience · doi:10.1016/j.isci.2023.107121 · Cited by 53 · see citing works
Glatfelter, G. C., Vandeputte, M. M., Chen, L., Walther, D., Tsai, M.-H. M., Shi, L., Stove, C. P., & Baumann, M. H. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06451-2 · Cited by 52 · see citing works
Self-citationPapsun, D. M., Krotulski, A. J., & Logan, B. K. (2022) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0000000000000787 · Cited by 51 · see citing works
Hunger, A., Kebrle, J., Rossi, A., & Hoffmann, K. J. (1960) · Helvetica Chimica Acta · doi:10.1002/hlca.19600430323 · Cited by 49 · see citing works
Dahan, A., Franko, T. S., Carroll, J. W., Craig, D. S., Crow, C., Galinkin, J. L., Garrity, J. C., Peterson, J., & Rausch, D. B. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1346109 · Cited by 49 · see citing works
Pottie, E., Tosh, D. K., Gao, Z., Jacobson, K. A., & Stove, C. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113934 · Cited by 48 · see citing works
Self-citationDe Luca, M. A., Tocco, G., Mostallino, R., Laus, A., Caria, F., Musa, A., Pintori, N., Ucha, M., Poza, C., Ambrosio, E., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109263 · Cited by 48 · see citing works
First Report on Brorphine: The Next Opioid on the Deadly New Psychoactive Substance Horizon?
Verougstraete, N., Vandeputte, M. M., Lyphout, C., Cannaert, A., Hulpia, F., Van Calenbergh, S., Verstraete, A. G., & Stove, C. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa094 · Cited by 44 · see citing works
Self-citationVandeputte, M. M., Verougstraete, N., Walther, D., Glatfelter, G. C., Malfliet, J., Baumann, M. H., Verstraete, A. G., & Stove, C. P. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03294-2 · Cited by 44 · see citing works
Self-citationIUPHAR themed review: Opioid efficacy, bias, and selectivity
Ramos‐Gonzalez, N., Paul, B., & Majumdar, S. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106961 · Cited by 43 · see citing works
Kozell, L. B., Eshleman, A. J., Wolfrum, K. M., Swanson, T. L., Bloom, S. H., Benware, S., Schmachtenberg, J. L., Schutzer, K. A., Schutzer, W. E., Janowsky, A., et al. (2024) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.002052 · Cited by 42 · see citing works
Nitazenes represent a growing threat to public health in Europe
Giraudon, I., Abel-Ollo, K., Vanaga-Arāja, D., Heudtlass, P., & Griffiths, P. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00024-0 · Cited by 40 · see citing works
Taoussi, O., Berardinelli, D., Zaami, S., Tavoletta, F., Basile, G., Kronstrand, R., Auwärter, V., Busardò, F. P., & Carlier, J. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03735-0 · Cited by 40 · see citing works
Blanckaert, P., Balcaen, M., Vanhee, C., Risseeuw, M., Canfyn, M., Desmedt, B., Van Calenbergh, S., & Deconinck, E. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3113 · Cited by 39 · see citing works
Analysis of highly potent synthetic opioid nitazene analogs and their positional isomers
Kanamori, T., Okada, Y., Segawa, H., Yamamuro, T., Kuwayama, K., Tsujikawa, K., & Iwata, Y. T. (2023) · Drug Testing and Analysis · doi:10.1002/dta.3415 · Cited by 39 · see citing works
Vandeputte, M. M., Tsai, M.-H. M., Chen, L., Glatfelter, G. C., Walther, D., Stove, C. P., Shi, L., & Baumann, M. H. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109939 · Cited by 39 · see citing works
Self-citationPottie, E., & Stove, C. P. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15570 · Cited by 37 · see citing works
Self-citationGriffiths, P. N., Seyler, T., De Morais, J. M., Mounteney, J. E., & Sedefov, R. S. (2024) · Addiction · doi:10.1111/add.16420 · Cited by 36 · see citing works
Bilel, S., Azevedo Neto, J., Arfè, R., Tirri, M., Gaudio, R. M., Fantinati, A., Bernardi, T., Boccuto, F., Marchetti, B., Corli, G., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109020 · Cited by 34 · see citing works
Walton, S. E., Krotulski, A. J., Glatfelter, G. C., Walther, D. M., Logan, B. K., & Baumann, M. H. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06292-5 · Cited by 33 · see citing works
Self-citation�ber neue starkwirkende Analgetika und ihre klinische Erprobung
Bromig, G. (1958) · Klinische Wochenschrift · doi:10.1007/bf01486702 · Cited by 29 · see citing works
Metabolic characterization of the new benzimidazole synthetic opioids - nitazenes
Jadhav, G. R., & Fasinu, P. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1434573 · Cited by 29 · see citing works
Berardinelli, D., Taoussi, O., Carlier, J., Tini, A., Zaami, S., Sundermann, T. R., Busardò, F. P., & Auwärter, V. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1360 · Cited by 28 · see citing works
Tsai, M.-H. M., Chen, L., Baumann, M. H., Canals, M., Javitch, J. A., Lane, J. R., & Shi, L. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00750 · Cited by 27 · see citing works
Self-citationExperimental considerations for the assessment of in vivo and in vitro opioid pharmacology
Hill, R., & Canals, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107961 · Cited by 24 · see citing works
Dependence studies of new compounds in the rhesus monkey, rat, and mouse, 1987.
Aceto, M. D. G., Bowman, E. R., Harris, L., & May, E. (1988) · PubMed · Cited by 22 · see citing works
Vandeputte, M. M., Vasudevan, L., & Stove, C. P. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108161 · Cited by 22 · see citing works
Self-citationHide and Seek: Overcoming the Masking Effect of Opioid Antagonists in Activity-Based Screening Tests
Cannaert, A., Deventer, M. H., Fogarty, M. F., Mohr, A. L. A., & Stove, C. P. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.309443 · Cited by 21 · see citing works
Self-citationPharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats
Truver, M. T., Smith, C. R., Garibay, N., Kopajtic, T. A., Swortwood, M. J., & Baumann, M. H. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108195 · Cited by 21 · see citing works
Self-citationGlatfelter, G. C., Partilla, J. S., & Baumann, M. H. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01227-8 · Cited by 21 · see citing works
Self-citationSantos, E. J., Banks, M. L., & Negus, S. S. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.001045 · Cited by 21 · see citing works
Kanamori, T., Okada, Y., Segawa, H., Yamamuro, T., Kuwayama, K., Tsujikawa, K., & Iwata, Y. T. (2024) · Drug Testing and Analysis · doi:10.1002/dta.3705 · Cited by 16 · see citing works
Assessment of the potential of novel and classical opioids to induce respiratory depression in mice
Hill, R., Sanchez, J., Lemel, L., Antonijevic, M., Hosking, Y., Mistry, S. N., Kruegel, A. C., Javitch, J. A., Lane, J. R., & Canals, M. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16199 · Cited by 15 · see citing works
Volz, M. R., & Moosmann, B. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.339978 · Cited by 13 · see citing works
The illegal drugs market is changing—is the UK prepared?
Eastwood, N., & Schlossenberg, S. S. (2023) · BMJ · doi:10.1136/bmj.p2421 · Cited by 8 · see citing works
[Dialkylaminoalkylbenzimidazoles of pharmacological interest. 3].
Sparatore, F., Boido, V., & Fanelli, F. (1968) · PubMed · Cited by 7 · see citing works
Alhosan, N., Cavallo, D., Santiago, M., Kelly, E., & Henderson, G. (2024) · doi:10.1101/2024.06.04.597322 · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- [16]United Nations Office on Drugs and Crime, The growing complexity of the opioid crisis. Global SMART Update, Volume 24, United Nations publication, Vienna, 2020. https://www.unodc.org/documents/scientific/Global_SMART_Update_2020-Vol.24-Eng-Final.pdf.
- [53]Bucha M, Eppakayala L, Maringanti TC, A Facile Synthesis and Molecular Docking for Anti-inflammatory Activity of 2-(4-Chlorobenzyl)-1-(2-(pyrrolidin-1-yl) ethyl)-1H-benzo [d] imidazol-5-amine and 2-(4-Chlorobenzyl)-1-((1-ethylpyrrolidin-2-yl) methyl)-1H-benzo [d] imidazol-5-amine, Indian Journal of Heterocyclic Chemistry 28 (2018) 321– 327.
- [62]Sparatore F, Boido V, Fanelli F, Dialchilamminoalchilbenzimidazoli d’interesse farmacologico., Farmaco 23 (1968) 344– 359. 5680377
Cited by
Sorted by citations
Vandeputte, M. M., & Stove, C. P. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110470 · Cited by 35 · see citing works
Self-citationClinical Experiences With the Nitazene Class of Synthetic Opioids: A Cohort Study
Roberts, D. M., Tisdell, B., Sajeev, M. F., Jiranantakan, T., Harvey, C., & Brown, J. A. (2025) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2025.06.619 · Cited by 20 · see citing works
Nitazenes: The Emergence of a Potent Synthetic Opioid Threat
Pereira, J. R. P., Quintas, A., & Neng, N. R. (2025) · Molecules · doi:10.3390/molecules30193890 · Cited by 21 · see citing works
Magny, R., Schiestel, T., M’Rad, A., Lefrère, B., Raphalen, J.-H., Ledochowski, S., Labat, L., Mégarbane, B., & Houzé, P. (2025) · Metabolites · doi:10.3390/metabo15060371 · Cited by 14 · see citing works
Kozell, L. B., Eshleman, A. J., Wolfrum, K. M., Swanson, T. L., Schutzer, K. A., Schutzer, W. E., & Abbas, A. I. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110512 · Cited by 12 · see citing works
Latest developments in small molecule analgesics: heterocyclic scaffolds I
Evren, A. E., Kaya, A. Z., Karakaya, A., Tutuş, B., Güngör, E. M., Nuha, D., Osmani̇ye, D., Kaya, B., Çevik, U. A., Yurttaş, L., et al. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2546783 · Cited by 10 · see citing works
Zhu, D. T., Fitzgerald, N. D., Palamar, J. J., & Krotulski, A. J. (2026) · Addiction · doi:10.1111/add.70378 · Cited by 8 · see citing works
Dugues, P., Rabai, A., Chenorhokian, S., Pfau, G., Cherki, S., Bellouard, M., Alvarez, J. C., & Larabi, I. A. (2025) · Toxicologie Analytique et Clinique · doi:10.1016/j.toxac.2025.07.002 · Cited by 6 · see citing works
Endogenous opiates and behavior: 2024
Bodnar, R. J. (2025) · Peptides · doi:10.1016/j.peptides.2025.171422 · Cited by 5 · see citing works
Tomiyama, K.-I., & Funada, M. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117361 · Cited by 4 · see citing works
Malzacher, J., Pulver, B., Heller, N., Brockbals, L., Bolliger, S. A., Kræmer, T., Steuer, A. E., & Poetzsch, S. N. (2025) · International Journal of Legal Medicine · doi:10.1007/s00414-025-03627-7 · Cited by 4 · see citing works
Mayer, A., Montgomery, N., Hughes, E., Birks Ang, B., & Johnson, O. E. (2026) · Forensic Science International · doi:10.1016/j.forsciint.2025.112717 · Cited by 4 · see citing works
Truver, M. T., Roman, M., Gomonit, M. M., Gréen, H., Kronstrand, R., & Persson, M. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04407-x · Cited by 4 · see citing works
The Nitazene Era: A Critical Turning Point in the Synthetic Opioid Crisis Beyond Fentanyl
Dow, L. F., Abisogun, A. A., Berida, T. I., Krishnan, S. C., Rathnayake, U., & Lindsley, C. W. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00696 · Cited by 2 · see citing works
Biotransformation and kinetics of selected benzimidazole synthetic opioids in human hepatocytes
Jadhav, G., & Fasinu, P. S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1656437 · Cited by 1 · see citing works
Jahan, K., Glatfelter, G. C., Sanchez, J., Maitland, A. D., Bonifazi, A., Saab, E., Keegan, B. M., Rais, R., Bi, G., Gomez, J. L., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119079 · Cited by 1 · see citing works
Self-citationKalajian, E. J., Stettler, M. K., Smith, G. D., & Negro, C. A. D. (2026) · The Journal of Physiology · doi:10.1113/jp291442 · Cited by 1 · see citing works
Maxwell, M. K., Anwar, A. I., Hasoon, J., & Kaye, A. D. (2026) · Current Pain and Headache Reports · doi:10.1007/s11916-026-01525-0
“Although nitazenes are often discussed as a class, minimal structural differences at the benzimidazole core, the N, N-dialkylaminoethyl side chain, as well as the para-substituted benzyl ring can profoundly alter receptor binding, potency, metabolism, and expected toxicity [17].”
Rehn, J., Andréll, C., Hansson, J., Troberg, K., Isendahl, P., Bråbäck, M., Svensson, L., Byrsell, F., Claesson, A., & Håkansson, A. (2025) · medRxiv · doi:10.64898/2025.12.19.25342601
Acute toxicity and sex-dependent lethality of isotonitazene in fischer 344 rats
Hernandez, Y. L., Vinerean, H. V., & Aggarwal, S. (2026) · Frontiers in Toxicology · doi:10.3389/ftox.2026.1818684
Coordinated subpocket engagement underlies nitazene potency at the µ-opioid receptorPreprint
Robinson, M. J., Chen, L., Thakur, A., Lee, K.-H., & Shi, L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.27.721072
Mechanistic insights into nitazenes at the μ-opioid receptor
Xia, L., Jin, M., & Lu, L. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.04.009
Feng, Y., Li, Y., Zhao, B., Zhao, C., Li, J., Yang, L., Zu, B., & Dou, X. (2026) · Analytical Methods · doi:10.1039/d6ay00429f
Commentary on Zhu et al .: Nitazenes—Tracking a moving target from linked United States databases
Stove, C. P., & Vandeputte, M. M. (2026) · Addiction · doi:10.1111/add.70480
Self-citationDetermination of nitazenes in postmortem casework and their prevalence in the State of Maryland
Fagiola, M., & Phipps, R. (2026) · Journal of Analytical Toxicology · doi:10.1093/jat/bkag031
Untargeted LC-HRMS impurity profiling for forensic chemical intelligence
Caprari, C., Ferri, E., Rossetti, P., Gregori, A., Citti, C., & Cannazza, G. (2026) · Forensic Chemistry · doi:10.1016/j.forc.2026.100755
Röhrig, J., Sutter, L., Witsch, N., Rademacher, L., & Cabanis, M. (2026) · medRxiv · doi:10.64898/2026.05.28.26354329
Rombolà, F., Maurizzi, D., Silla, A., Caliceti, C., Bilel, S., Hrelia, P., Malaguti, M., Lenzi, M., & Marti, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125360
Preclinical pharmacology of N-pyrrolidino “nitazene” opioids appearing in nonmedical drug markets
Glatfelter, G. C., Maitland, A. D., Gonzalez, N. R., Walther, D. M., Chen, L., Shi, L., & Baumann, M. H. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104977
Self-citationRehn, J., Andréll, C., Hansson, J., Troberg, K., Isendahl, P., Bråbäck, M., Svensson, L., Byrsell, F., Claesson, A., & Håkansson, A. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-115692
Coordinated Subpocket Engagement Underlies Nitazene Potency at the μ-Opioid Receptor
Robinson, M. J., Chen, L., Thakur, A., Lee, K.-H., & Shi, L. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00311
Les nouvelles drogues de synthèse et leur moyen de détection
Alvarez, J. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.05.017
Niżnik, Ł., & Jurowski, K. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.112263
Li, Y., Liao, L., Yang, L., Zhang, L., Zhang, Q., Zhang, J., Lin, Y., & Zheng, C. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c03154
Tian, X., Jiao, Y., Liu, C., Song, Y., Hussain, S., Hao, Y., Alharbi, S., Wang, Y., Liao, Q., & Gao, R. (2026) · The Analyst · doi:10.1039/d6an00886k
- Authors
- Vandeputte, M. M., Glatfelter, G. C., Walther, D., Layle, N. K., St. Germaine, D. M., Ujváry, I., Iula, D. M., Baumann, M. H., & Stove, C. P.
- Affiliations
- Ghent University (BE)
- National Institutes of Health (US)
- Cayman Chemical (United States) (US)
- Corresponding author
- Stove, Christophe P.
- ORCID
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2024-12
- Volume
- 210
- Pages
- 107503
- ISSN
- 1043-6618 (ISSN-L)
- PMC
- PMC11655282
- OpenAlex
- W4404149532
- Cited by
- 35
- References
- 62
- Citations by year
- 2026: 22 · 2025: 13
- FWCI
- 8.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmacological Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Intramural Research Program, National Institute on Drug Abuse
- Bijzonder Onderzoeksfonds UGent
- Research Foundation Flanders
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- nitazenes, recreational drugs, mu-opioid receptor, structure-activity relationship, antinociception, locomotor activity, body temperature, β-arrestin2, drug risk assessment, new psychoactive substances
- MeSH terms
- Analgesics, Opioid, Animals, Behavior, Animal, Benzimidazoles, Brain, Humans, Male, Mice, Inbred C57BL, Motor Activity, Illicit Drugs, Structure-Activity Relationship, Rats, Sprague-Dawley, Receptors, Opioid, mu, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
